Comparing of Protagonist Therapeutics Inc. (PTGX) and resTORbio Inc. (NASDAQ:TORC)

Protagonist Therapeutics Inc. (NASDAQ:PTGX) and resTORbio Inc. (NASDAQ:TORC) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Protagonist Therapeutics Inc. 11 0.00 17.24M -1.94 0.00
resTORbio Inc. 5 -0.02 16.54M -1.37 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Protagonist Therapeutics Inc. and resTORbio Inc.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics Inc. 159,334,565.62% -40.8% -32.5%
resTORbio Inc. 309,077,998.28% -33% -31%


Protagonist Therapeutics Inc.’s Current Ratio and Quick Ratio are 5 and 5 respectively. The Current Ratio and Quick Ratio of its competitor resTORbio Inc. are 31.4 and 31.4 respectively. resTORbio Inc. therefore has a better chance of paying off short and long-term obligations compared to Protagonist Therapeutics Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Protagonist Therapeutics Inc. and resTORbio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Protagonist Therapeutics Inc. 0 0 0 0.00
resTORbio Inc. 0 1 0 2.00

Competitively resTORbio Inc. has a consensus target price of $3, with potential upside of 156.41%.

Insider & Institutional Ownership

Protagonist Therapeutics Inc. and resTORbio Inc. has shares held by institutional investors as follows: 99.4% and 54.1%. Insiders held roughly 2.1% of Protagonist Therapeutics Inc.’s shares. Comparatively, 38.1% are resTORbio Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Protagonist Therapeutics Inc. -10.55% -11.49% 9.33% 36.22% 58.11% 63.74%
resTORbio Inc. 1.02% 5.73% 35.32% 22.11% -27.51% 26.22%

For the past year Protagonist Therapeutics Inc. was more bullish than resTORbio Inc.


resTORbio Inc. beats Protagonist Therapeutics Inc. on 7 of the 11 factors.

Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. It primarily focuses on developing oral peptide drugs. The companyÂ’s lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease (IBD); and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD. It is also developing PTG-300, an injectable hepcidin mimetic peptide that is in pre-clinical development stage to treat iron overload disorders, such as b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.